ArticleJournal of clinical microbiology2024
Evaluation of the Vitek 2 system for antifungal susceptibility testing of
Article in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- 30-day mortality and antifungal resistance in confirmed Candida auris bloodstream infections (BSI): a systematic review and meta-analysis.Infection · 2026Review
- Evaluation of Sensititre YeastOne for antifungal susceptibility testing ofJournal of clinical microbiology · 2026Article
- Review
- Comparative assessment of the broth microdilution and VITEK 2 systems for antifungal susceptibility testing of Candida auris (Candidozyma auris) Isolates.BMC microbiology · 2026Article
- Epidemiology and antimicrobial resistance of pathogens in granulomatous mastitis: A multicenter study in Guangdong, China.iScience · 2025Article
- Epidemiological and microbiological characterization of Candidozyma auris (Candida auris) isolates from a tertiary hospital in Cairo, Egypt: an 18-month study.Scientific reports · 2025Article
- Evaluation of the MIC test strips for antifungal susceptibility testing ofJournal of clinical microbiology · 2025Article
- Brown locusts, Locustana pardalina, host fluconazole-resistant Candidozyma (Candida) auris, closely related to Clade III clinical strains.Medical mycology · 2025Article
- Head-to-Head Comparison of Etest, MICRONAUT-AM EUCAST and Reference Broth Microdilution-Based CLSI Results forJournal of fungi (Basel, Switzerland) · 2025Article
- Diagnostic Approaches forMicroorganisms · 2025Review
- Review
- Comparison of broth microdilution and Etest® methods for susceptibility testing of amphotericin B in Candida auris.Medical mycology · 2025Article
- Analysis of Candidozyma auris - an emerging threat in intensive care units.GMS hygiene and infection control · 2025Article
- Genetic microevolution of clinicalEmerging microbes & infections · 2024Article
- Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing ofAntibiotics (Basel, Switzerland) · 2024Article
- Phenotypic and Genotypic Characterization of Resistance and Virulence Markers inJournal of fungi (Basel, Switzerland) · 2024Article
- Emergence of the novel sixthMicrobiology spectrum · 2024Article
- Detection ofAnnals of Saudi medicineArticle
- Spectrum and management of rareTherapeutic advances in infectious diseaseReview
- Identification and antifungal resistance profiling ofAnnals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
Abstract
Although the Vitek 2 system is broadly used for antifungal susceptibility testing of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.